research and publications
Dysbiosis and Neutrophilic Inflammation
Improper regulation of MMP-9 activity associated with numerous disorders such as COPD, lung cancer, asthma, emphysema, cystic fibrosis, fibrotic lung diseases such as Idiopathic pulmonary fibrosis (IPB) and COVID-19.
resB® decreases MMP-9 levels in Human lung epithelial cells
- resB® was found to reverse MMP-9 cascade in in vitro dysbiosis model of lung epithelial cells.
- resB® was found to reduce neutrophils, cell count and MPO activity in in vivo model of dysbiosis.
- resB® downregulates MMP-9 gene expression in mouse lung tissue.
resB® downregulates the mRNA expression and levels of MMP-9 protein in E.coli.
resB® prevents lung tissue damage in in-vivomodel of dysbiosis (Mice)
resB® reduces BAL Neutrophils, Cell Count, MPO, CRP, MMP-9 mRNA as well as Protein Levels, in In-vivo model of Lung Dysbiosis (Mice).
Clinical Studies of resB® Lung Support
resB® Lung Support: Trial in Healthy and Asthma patients (Completed)
resB® Lung Support: Trial in COPD and NCFBE patients (Ongoing)
